M. tuberculosis persistence, latency, and drug tolerance

Tuberculosis

Volumn 84, Issue 1-2, 2004, Pages 29-44

  Gomez, James E ^a   McKinney, John D ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Dormancy; Drug tolerance; Latency; Persistence

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BCG VACCINE; CORTICOSTEROID; DNA VACCINE; INFLIXIMAB; ISONIAZID; METRONIDAZOLE; MINOCYCLINE; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

BCG VACCINATION; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE COURSE; DRUG SENSITIVITY; DRUG TOLERANCE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; LATENT PERIOD; MEDICAL LITERATURE; MEDICAL RESEARCH; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RESERVOIR; TUBERCULOSIS;

EID: 0347091999     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2003.08.003     Document Type: Conference Paper

References (107)

1. McDermott W. Inapparent infection: relation of latent and dormant infection to microbial persistence. Pub Health Rep 1959;74:485-99.
2. Ehrlich P. Address in pathology on chemotherapeutics: scientific principles, methods, and results. Lancet 1913; 2:445-51.
3. Waksman SA. The conquest of tuberculosis. London: Robert Hale Limited; 1964.
4. Dye C, Scheele S, Dolin P, et al. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 1999;282:677-86.
5. Amberson JB. The significance of latent forms of tuberculosis. N Engl J Med 1938;219:572-6.
6. Ghon A. The primary complex in human tuberculosis and its significance. Am Rev Tuberc 1923;7:314-7.
7. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996; 64:2062-9.
8. Corper HJ, Conn ML. The viability and virulence of old cultures of tubercle bacilli: studies on twelve-year broth cultures maintained at incubator temperature. Am Rev Tuberc 1933;28:856-74.
9. Wayne LG, Sohaskey CD. Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol 2001;55: 139-63.
10. Lillebaek T, Dirksen A, Baess I, et al. Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J Infect Dis 2002; 185:401-4.
11. van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999;341:1174-9.
12. Sonnenberg P, Murray J, Glynn JR, et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001;358:1687-93.
13. Styblo K. Epidemiology of tuberculosis. The Hague: Royal Netherlands Tuberculosis Association; 1991.
14. Rich AR. The pathogenesis of tuberculosis. Springfield, IL: Charles C. Thomas; 1944.
15. Dannenberg Jr AM. Immunopathogenesis of pulmonary tuberculosis. Hosp Pract (Off Ed) 1993;28:51-8.
16. Balasubramanian V, Wiegeshaus EH, Taylor BT, et al. Pathogenesis of tuberculosis: pathway to apical localization. Tuberc Lung Dis 1994;75:168-78.
17. Opie EL, Aronson JD. Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions. Arch Pathol 1927;4:1-21.
18. Feldman WH, Baggenstoss AH. The occurrence of virulent tubercle bacilli in presumably non-tuberculous lung tissue. Am J Pathol 1939;15:501-15.
19. Feldman WH. The residual infectivity of the primary complex of tuberculosis. Am J Pathol 1938;14:473-90.
20. Sweany HC, Levinson SA, Stadnichenko AMS. Tuberculous infection in people dying of causes other than tuberculosis. Am Rev Tuberc 1943;47:131-73.
21. Hernandez-Pando R, Jeyanathan M, Mengistu G, et al. Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 2000;356:2133-8.
22. Beck F, Yegian D. A study of the tubercle bacillus in resected pulmonary lesions. Am Rev Tuberc 1952;66: 44-50.
23. Medlar EM, Bernstein S, Steward DM. A bacteriologic study of resected tuberculous lesions. Am Rev Tuberc 1952;66:36-43.
24. American Trudeau Society. Report of a panel discussion on survival, revival of tubercle bacilli in healed and tuberculous lesions. Am Rev Tuberc 1953; 68: 477-95.
25. Hobby GL, Auerbach O, Lenert TF, et al. The late emergence of M. tuberculosis in liquid cultures of pulmonary lesions resected from humans. Am Rev Tuberc 1954;70:191-218.
26. Loring WE, Vandiviere HM. The treated pulmonary lesion and its tubercle bacillus. I. Pathology and pathogenesis. Am J Med Sci 1956;232:20-9.
27. Vandiviere HM, Loring WE, Melvin I, et al. The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection. Am J Med Sci 1956;232:30-7.
28. Wayne LG. The bacteriology of resected tuberculous pulmonary lesions. I. The effect of Interval between reversal of infectiousness and subsequent surgery. Am Rev Tuberc Pulm Dis 1956;74:376-87.
29. McCune RM, Tompsett R. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculosis infection to the latent state by the administration of tuberculosis and a companion drug. J Exp Med 1956; 104:763-802.
30. McCune RM, Tompsett R, McDermott W. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug susceptible bacilli in the tissues despite prolonged antimicrobial therapy. J Exp Med 1956;104: 737-42.
31. McCune RM, Feldman FM, Lambert HP, et al. Microbial persistence II. Characteristics of the sterile state of tubercle bacilli. J Exp Med 1966;123:469-86.
32. McCune RM, Feldman FM, Lambert HP, et al. Microbial persistence I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med 1966;123:445-68.
33. Barclay WR, Ebert RH, Le Roy GV, et al. Distribution and excretion of radioactive isoniazid in tuberculosis patients. JAMA 1953;151:1384-8.
34. Haapanen JH, Kass I, Gensini G, et al. Studies on the gaseous content of tuberculous cavities. Am Rev Respir Dis 1959;80:1-5.
35. Hobby GL, Lenert TF. The in vitro action of antituberculous agents against multiplying and non-multiplying microbial cells. Am Rev Tuberc 1957;76:1031-48.
36. Hobby GL, Meyer K, Chaffee E. Observations on the mechanism of action of penicillin. Proc Soc Exp Biol Med 1942;50:281-5.
37. Tomasz A, Albino A, Zanati E. Multiple antibiotic resistance in a bacterium with suppressed autolytic system. Nature 1970;227:138-40.
38. Tuomanen E. Phenotypic tolerance: the search for betalactam antibiotics that kill nongrowing bacteria. Rev Infect Dis 1986;8:S279-91.
39. Wallis RS, Patil S, Cheon SH, et al. Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999;43:2600-6.
40. Höner zu Bentrup K, Russell DG. Mycobacterial persistence: adaptation to a changing environment. Trends Microbiol 2001;9:597-605.
41. Dahl JL, Kraus CN, Boshoff HI, et al. The role of Rel Mtb-mediated adaption to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci USA 2003;100:10026-31.
42. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393:537-43.
43. Alland D, Kramnik I, Weisbrod TR, et al. Identification of differentially expressed mRNA in prokaryotic organisms by customized amplification libraries (DECAL): the effect of isoniazid on gene expression in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1998;95:13227-32.
44. Alland D, Steyn AJ, Weisbrod T, et al. Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition. J Bacteriol 2000;182:1802-11.
45. Michele TM, Ko C, Bishai WR. Exposure to antibiotics induces expression of the Mycobacterium tuberculosis sigF gene: implications for chemotherapy against mycobacterial persistors. Antimicrob Agents Chemother 1999; 43:218-25.
46. Wilson M, DeRisi J, Kristensen HH, et al. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci USA 1999;96:12833-8.
47. Hu YM, Butcher PD, Sole K, et al. Protein synthesis is shut down in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. FEMS Microbiol Lett 1998;158:139-45.
48. Wayne L. Growth of Mycobacterium tuberculosis from resected specimens under various atmospheric conditions. Am Rev Tuberc 1954;70:910-1.
49. Wayne LG. The bacteriology of resected tuberculous pulmonary lesions. II. Observations on bacilli which are stainable but which cannot be cultured. Am Rev Respir Dis 1960;82:370-7.
50. Wayne LG. Dynamics of submerged growth of Mycobacterium tuberculosis under aerobic and microaerophilic conditions. Am Rev Respir Dis 1976;114:807-11.
51. Wayne LG. Synchronized replication of Mycobacterium tuberculosis. Infect Immun 1977;17:528-30.
52. Wayne LG, Lin KY. Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect Immun 1982;37:1042-9.
53. Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J Clin Microbiol Infect Dis 1994; 13:908-14.
54. Parrish NM, Dick JD, Bishal WR. Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol 1998;6: 107-12.
55. Brooks JV, Furney SK, Orme IM. Metronidazole therapy in mice infected with tuberculosis. Antimicrob Agents Chemother 1999;43:1285-8.
56. Dhillon J, Allen BW, Hu YM, et al. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int J Tuberc Lung Dis 1998;2:736-42.
57. Walsh GP, Tan EV, Dela Cru EC, et al. The Phillipine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nature Med 1996;2:430-6.
58. Lurie M. Resistance to tuberculosis: experimental studies in native and acquired defensive mechanisms. Cambridge, MA: Harvard Univ. Press; 1964.
59. Orme IM, Collins FM. Mouse model of tuberculosis. In: Bloom BR, editor. Tuberculosis: pathogenesis, protection, and control. Washington, DC: ASM Press; 1994.
60. Medina E, North RJ. Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype. Immunology 1998;93:270-4.
61. Cooper AM, Dalton DK, Stewart TA, et al. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993;178:2243-7.
62. Flynn JL, Chan J, Triebold KJ, et al. An essential role for interferon-γ in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993;178:2249-54.
63. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-72.
64. MacMicking JD, North RJ, LaCourse R, et al. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci USA 1997;94: 5243-348.
65. Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001;69:1847-55.
66. Flynn JL, Scanga CA, Tanaka KE, et al. Effects of aminoguanidine on latent murine tuberculosis. J Immunol 1998;160:1796-803.
67. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
68. Scanga CA, Mohan VP, Yu K, et al. Depletion of CD4(+) T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon gamma and nitric oxide synthase 2. J Exp Med 2000;192: 347-58.
69. van Pinxteren LA, Cassidy JP, Smedegaard BH, et al. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 2000;30: 3689-98.
70. Chan K, Knaak T, Satkamp L, et al. Complex pattern of Mycobacterium marinum gene expression during long-term granulomatous infection. Proc Natl Acad Sci USA 2002;99: 3920-5.
71. Rees RJW, Hart PD. Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts. Br J Exp Pathol 1961;42:83-8.
72. Wallace JG. The heat resistance of tubercle bacilli in the lungs of Infected mice. Am Rev Respir Dis 1961; 83:866-71.
73. McDermott W. Microbial persistence. Yale J Biol Med 1958; 30:257-91.
74. Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental shortcourse chemotherapy. Bull Int Union Tuberc 1978;53:5-12.
75. Orme IM. The immunopathogenesis of tuberculosis: a new working hypothesis. Trends Microbiol 1998;6:94-7.
76. LeCoeur HF, Lagrange PH, Truffot-Pernot C, et al. Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice. Clin Exp Immunol 1989;76:458-62.
77. Khomenko AG. The variability of Mycobacterium tuberculosis in patients with cavltary pulmonary tuberculosis in the course of chemotherapy. Tubercle 1987;68:243-53.
78. McCune R, Lee SH, Deuschle K, et al. Ineffectiveness of isoniazid in modifying the phenomenon of microbial persistence. Am Rev Tuberc Pulm Dis 1957;76:1106-9.
79. Miyazaki E, Chaisson RE, Bishal WR. Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis. Antimicrob Agents Chemother 1999; 43:2126-30.
80. Lounis N, Bentoucha A, Truffot-Pernot C, et al. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001;45:3482-6.
81. Scanga CA, Mohan VP, Joseph H, et al. Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect Immun 1999;67:4531-8.
82. Flynn JL, Chan J. Tuberculosis: latency and reactivation. Infect Immun 2001;69:4195-201.
83. Glickman MS, Jacobs Jr WR. Microbial pathogenesis of Mycobacterium tuberculosis: dawn of a discipline. Cell 2001;104:477-85.
84. Abbott A. Live lung tissue enlisted in fight against tuberculosis. Nature 2002;415:823.
85. McKinney JD. In vivo veritas: the search for TB drug targets goes live. Nat Med 2000;6:1330-3.
86. Glickman MS, Cox JS, Jacobs Jr WR. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol Cell 2000;5:717-27.
87. Cox JS, Chen B, McNeil M, et al. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature 1999;402:79-83.
88. Segal W, Bloch H. Biochemical differentiation of Mycobacterium tuberculosis grown in vivo and in vitro. J Bacteriol 1956;72:132-41.
89. McKinney JD, Höner zu Bentrup K, Munoz-Elias EJ, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000;406:735-8.
90. Stewart GR, Snewin VA, Walzl G, et al. Overexpression of heat-shock proteins reduces survival of Mycobacterium tuberculosis in the chronic phase of infection. Nat Med 2001;7:732-7.
91. Zahrt TC, Deretic V. Mycobacterium tuberculosis signal transduction system required for persistent infections. Proc Natl Acad Sci USA 2001;98:12706-11.
92. Mehrotra J, Bishai WR. Regulation of virulence genes in Mycobacterium tuberculosis. Int J Med Microbiol 2001; 291:171-82.
93. Kaushal D, Schroeder BG, Tyagi S, et al. Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative sigma factor, SigH. Proc Natl Acad Sci USA 2002; 99:8330-5.
94. Steyn AJC, Collins DM, Hondalus MK, et al. Mycobacterium tuberculosis WhiB3 interacts with RpoV to affect host survival but is dispensable for in vivo growth. Proc Natl Acad Sci USA 2002;99:3147-52.
95. Centers for Disease Control and Prevention. Tuberculosis morbidity among US-born, foreign-born populations - United States, 2000. MMWR 2002; 51: 101-4.
96. Institute of Medicine. Ending neglect: the elimination of tuberculosis in the United States. Washington, DC: National Academy Press, 2000.
97. Perlman DC, El-Helou P, Salomon N. Tuberculosis in patients with human immunodeficiency virus infection. Semin Respir Infect 1999;14:344-52.
98. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009-21.
99. Andersen P, Munk ME, Pollock JM, et al. Specific immune-based diagnosis of tuberculosis. Lancet 2000;356: 1099-104.
100. Centers for Disease Control and Prevention. Targeted tuberculin testing, treatment of latent tuberculosis infection. MMWR 2000; 49(RR-6): 1-52.
101. World Health Organization. WHO expert committee on leprosy. WHO Tech Rep Ser 1998; 874: 1-43.
102. Lowrie DB, Tascon RE, Bonato VLD, et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999; 400:269-71.
103. Sharma AK, Khuller GK. DNA vaccines: future strategies and relevance to intracellular pathogens. Immunol Cell Biol 2001;79:537-46.
104. Hu Y, Coates ARM, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:653-7.
105. Fenhalls G, Stevens L, Moses L, et al. In situ detection of Mycobacterium tuberculosis transcripts in human lung granulomas reveals differential expression in necrotic lesions. Infect Immun 2002;70:6330-8.
106. Camacho LR, Ensergueix D, Perez E, Gicquel B, Guilhot C. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol Microbiol 1999;34:257-67.
107. Taylor JL, Turner OC, Basaraba RJ, Belisle JT, Huygen K, Orme IM. Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect Immun 2003; 71:2192-8.